Key Financial
Guidance 2022

FY2022 Revenue US$270 - $280m
FY2022 Adjusted EBITDA
US$47 - $53m
Cash & Receivables US$230m
Laboratory and rapid
at-home tests
26 million+

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

14 Mar 23
New Business Strategy Focused on Precision Oncology LONDON and HONG KONG, March 14, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics and precision oncology company, today announced financial results for the fourth quarter and full